FarmaMondo Partners with Cordex to Expand Zemcelpro
LUGANO, Switzerland & MONTREAL, Canada, July 16, 2026 FarmaMondo Group has entered an exclusive commercial partnership with Cordex Biologics...
acute kidney injury
Advertisement
Dimerix Secures Funding to Advance DMX-200 Phase 3 Trial
MELBOURNE, Australia, July 17, 2026 Dimerix Limited has secured an initial AU$10 million non-dilutive loan facility to strengthen its...
Arch Biopartners Accelerates IL-32 Chronic Kidney Disease Drug Program
TORONTO, July 17, 2026 Arch Biopartners Inc. has taken a significant step toward advancing its pre-Investigational New Drug (pre-IND)...
Mission Sells MTX652 to Dimerix in $292M Deal
Cambridge, UK, July 17, 2026 Mission Therapeutics announced the divestment of its Phase 2-ready USP30 inhibitor MTX652 to Dimerix...
SeaStar Promotes Pediatric AKI Awareness
DENVER, July 14, 2026 SeaStar Medical announced its support for multiple educational initiatives aimed at improving the diagnosis and...
Advertisements
CalciMedica Receives FDA Clearance to Continue Auxora KOURAGE Trial
LA JOLLA, Calif., June 24, 2026 CalciMedica, Inc. announced that the U.S. Food and Drug Administration (FDA) has completed...
Edesa Biotech Reports Positive Paridiprubart AKI Data
TORONTO, June 5, 2026 Edesa Biotech, Inc. announced new exploratory analyses demonstrating positive clinical signals for paridiprubart (EB05), its...
Arch Biopartners Advances Phase II AKI Trial
TORONTO, May 22, 2026 Arch Biopartners announced that Royal Columbian Hospital (RCH) in British Columbia has dosed its first...
Akebia Therapeutics Doses First in AKB-9090 Trial
CAMBRIDGE, Mass., April 13, 2026 Akebia Therapeutics, Inc., a biopharmaceutical company focused on kidney disease, has announced that the...
Arch Biopartners Expands Phase II Kidney Injury Trial in Canada
TORONTO, November 5, 2025 — Arch Biopartners Inc. (TSXV: ARCH, OTCQB: ACHFF) announced that the Fraser Health Research Ethics...
Advertisement
